Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market following launch. The report evaluates physicians’ current awareness and familiarity with Entyvio, the advantages and disadvantages compared to currently available therapies, and the current and anticipated usage of the drug; as well as the drug’s promotional activity.

Questions Answered in This Report:

  • Familiarity and awareness among gastroenterologists: What is the extent of physicians’ awareness of, and interest in Entyvio? How familiar are surveyed gastroenterologists with Entyvio’s prescribing information?

  • What are the perceived clinical advantages and disadvantages of Entyvio compared to other marketed therapies used in moderate to severe UC and CD?

  • To what extent is Entyvio currently being used by surveyed gastroenterologists? Where does Entyvio fit in the treatment algorithm among prescribers? When do non-prescribers expect to initiate trial usage?

  • What promotional messages are being employed by Takeda?

Scope:

This LaunchTrends report series will track the post-launch awareness, trial, and usage of vedolizumab (Entyvio) among gastroenterologists for the treatment of moderate to severe UC and CD. Three waves of the syndicated report will assess physician perceptions at one month, six months and one year post-launch. The reports will further explore where Entyvio is being placed in the treatment algorithm and in which patient types, strengths and weaknesses of the product profile compared to other agents, and the overall impact of the launch on the market landscape.

Markets covered: United States.

Primary research: Online survey of 72 gastroenterologists; qualitative interviews with 10 respondents.

Author(s): Adi Reske, Ph.D.